Business
WuXi Biologics Honored with 2025 Global Customer Value Leadership Recognition by Frost & Sullivan
WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced that it has been honored with the Frost & Sullivan's 2025 Global Customer Value Leadership Recognition in the biologics CRDMO industry.
About this update from Wuxi Biologics (cayman) Inc.
[{"type":"text","content":"SHANGHAI, Oct. 20, 2025 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced that it has been honored with the Frost & Sullivan's 2025 Global Customer Value Leadership Recognition in the biologics CRDMO industry.","length":314,"tagName":"p"},{"type":"text","content":"Frost & Sullivan's recognition highlights WuXi Biologics' efforts to deliver exceptional customer value through technology innovation, operational excellence, and insight into evolving client needs. WuXi Biologics' fully integrated CRDMO platform supports seamless transitions from early discovery to late-stage manufacturing and commercialization. This streamlined approach reduces complexity and cost while accelerating timelines, establishing WuXi Biologics as a trusted single-source partner throughout the entire product lifecycle.","length":557,"tagName":"p"},{"type":"text","content":"As of June 30, 2025, WuXi Biologics has a total of 864 integrated projects, representing one of the largest portfolios of complex biologics in the industry. This portfolio includes 326 mAbs, 168 bispecifics & multispecifics, 225 ADCs, 80 fusion proteins, and 25 vaccines. The development time for mAbs from DNA to Investigational New Drug (IND) application has been shortened to 9 months, with an autoimmune disease project completed in just 6 months. By combining single-use technology (SUT) with a scale-out strategy, the company has manufactured over 300 batches at scales ranging from 4,000 to 16,000 liters across its global facilities, achieving a 98% success rate since 2022. At an equivalent scale, SUT manufacturing costs are comparable to those of stainless-steel systems. These milestones are underpinned by its world-class quality systems, which have achieved a 100% success rate in Pre-License Inspections (PLI) and have passed 44 inspections by global regulatory agencies, including 22 conducted by the U.S. FDA and EMA.","length":1043,"tagName":"p"},{"type":"text","content":""In a rapidly evolving global biopharmaceutical industry marked by rising healthcare demand and increasing geopolitical complexity, WuXi Biologics continues to lead the transformation of the CRDMO model. By expanding its international footprint, enhancing supply chain resilience, a...